Welcome to our dedicated page for Compass Pathways Plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
COMPASS Pathways plc filings document the regulatory record for a biotechnology company developing COMP360, a proprietary synthetic psilocybin formulation for mental health indications including treatment-resistant depression. Current reports disclose financial results, clinical and regulatory updates, investor presentation materials, and material agreements tied to debt facilities and securities offerings.
Proxy and other filings cover annual general meeting matters, board structure, committee assignments, compensation arrangements, and shareholder voting procedures. Capital-structure disclosures include American Depositary Shares, ordinary shares, pre-funded warrants, registration statement references, underwriting terms, and loan and security agreement amendments.
COMPASS Pathways plc reported a routine insider tax-related transaction by its Chief Executive Officer, Kabir Nath. On March 11, 2026, 13,131 Ordinary Shares were disposed of at $6.89 per share, but this was a tax-withholding disposition rather than an open-market sale. The shares were withheld by the company upon the vesting of restricted share units to cover tax obligations, so the CEO did not actively trade these shares in the market. Following this event, Nath directly owned 191,990 Ordinary Shares. Each Ordinary Share may be represented by an American Depositary Share on the U.S. market.
COMPASS Pathways plc Chief Financial Officer Teri Loxam reported a routine tax-related share disposition. On the vesting of restricted share units, 1,781 Ordinary Shares were withheld by the company at a value of $6.89 per share to satisfy tax withholding obligations. After this withholding, Loxam directly owns 77,002 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
COMPASS Pathways plc Chief Financial Officer Teri Loxam reported a tax-related share disposition. On the transaction date, 4,467 Ordinary Shares were withheld by the company upon vesting of restricted share units to satisfy tax withholding obligations. After this withholding, Loxam directly owned 78,783 Ordinary Shares.
Compass Pathways plc is raising new equity capital through an underwritten public offering of 17,500,000 American Depositary Shares (ADSs) at $8.00 per ADS and pre-funded warrants to purchase up to 1,250,000 ADSs at $7.999 per warrant. Underwriters also have a 30‑day option to buy up to 2,812,500 additional ADSs. Gross proceeds are expected to be $150.0 million before fees and expenses. All securities are being sold by the company, with closing expected around February 20, 2026, subject to customary conditions.
The pre-funded warrants carry a nominal exercise price of $0.0001 per ADS, are exercisable immediately, and include a Beneficial Ownership Limitation generally capped at 9.99%, which holders can adjust up to 19.99% with notice. The company, its officers and directors have agreed to a 60‑day lock-up on additional sales.
Compass Pathways intends to use net proceeds, together with existing cash, to fund its COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 COMP360 PTSD program, accelerate commercial readiness activities, and for working capital and general corporate purposes.
COMPASS Pathways plc is offering 17,500,000 American Depositary Shares and pre-funded warrants to purchase 1,250,000 ADSs. The ADSs are being sold at $8.00 per ADS and the pre-funded warrants at $7.9999 each, with aggregate public offering proceeds shown as $149,999,875 and estimated net proceeds of approximately $140.5 million after underwriting discounts and estimated offering expenses.
The offering includes a 30-day underwriters' option to purchase up to 2,812,500 additional ADSs. The company intends to use net proceeds to fund its ongoing COMP005 and COMP006 Phase 3 trials for treatment-resistant depression, a Phase 2b/3 trial in PTSD, accelerate commercial readiness activities, and for working capital and general corporate purposes.
AtaiBeckley Inc. filed Amendment No. 6 to its Schedule 13D on COMPASS Pathways, reporting beneficial ownership of 4,764,710 ordinary shares, or 4.96% of the company’s ordinary shares outstanding as of October 30, 2025.
The filing notes that 96,017,044 ordinary shares were outstanding on that date and that AtaiBeckley directly holds the reported securities. It lists a series of open market sales of American Depositary Shares between November 24, 2025 and January 21, 2026 at prices generally between about $5.08 and $7.49 per share. As of January 21, 2026, AtaiBeckley states it ceased to be the beneficial owner of more than five percent of COMPASS Pathways’ ordinary shares.
AtaiBeckley Inc. filed Amendment No. 6 to its Schedule 13D on COMPASS Pathways, reporting beneficial ownership of 4,764,710 ordinary shares, or 4.96% of the company’s ordinary shares outstanding as of October 30, 2025.
The filing notes that 96,017,044 ordinary shares were outstanding on that date and that AtaiBeckley directly holds the reported securities. It lists a series of open market sales of American Depositary Shares between November 24, 2025 and January 21, 2026 at prices generally between about $5.08 and $7.49 per share. As of January 21, 2026, AtaiBeckley states it ceased to be the beneficial owner of more than five percent of COMPASS Pathways’ ordinary shares.
COMPASS Pathways is offering $150,000,000 of American Depositary Shares and pre-funded warrants in a primary equity raise, plus ADSs issuable on warrant exercise. Underwriters also have a 30-day option to buy up to an additional $22.5 million of ADSs. Net proceeds are earmarked mainly to fund COMP360 Phase 3 trials in treatment-resistant depression, a Phase 2b/3 PTSD trial, and commercial launch preparation, alongside general corporate uses.
The company recently reported that both pivotal Phase 3 trials, COMP005 and COMP006, met their primary endpoints, with 25 mg COMP360 showing highly statistically significant and clinically meaningful MADRS improvements versus control and a generally well-tolerated safety profile. Preliminary cash and cash equivalents were about $149.6 million as of December 31, 2025, and management warns that without this or similar financing there is substantial doubt about the ability to continue as a going concern.
COMPASS Pathways is offering $150,000,000 of American Depositary Shares and pre-funded warrants in a primary equity raise, plus ADSs issuable on warrant exercise. Underwriters also have a 30-day option to buy up to an additional $22.5 million of ADSs. Net proceeds are earmarked mainly to fund COMP360 Phase 3 trials in treatment-resistant depression, a Phase 2b/3 PTSD trial, and commercial launch preparation, alongside general corporate uses.
The company recently reported that both pivotal Phase 3 trials, COMP005 and COMP006, met their primary endpoints, with 25 mg COMP360 showing highly statistically significant and clinically meaningful MADRS improvements versus control and a generally well-tolerated safety profile. Preliminary cash and cash equivalents were about $149.6 million as of December 31, 2025, and management warns that without this or similar financing there is substantial doubt about the ability to continue as a going concern.
Compass Pathways reported strongly positive topline results from both pivotal Phase 3 trials of its COMP360 psilocybin treatment for treatment‑resistant depression. In COMP005, a single 25 mg dose showed a highly statistically significant mean MADRS improvement versus placebo of -3.6 points at Week 6 (p<0.001), with rapid onset from the day after dosing and durability out to Week 26 for many responders. In COMP006, two 25 mg doses given three weeks apart achieved a -3.8‑point difference versus 1 mg at Week 6 (p<0.001), with 39% of patients reaching a clinically meaningful ≥25% MADRS reduction. Across more than 800 treated patients in these Phase 3 arms, COMP360 was generally well-tolerated; most adverse events such as headache, nausea, anxiety and visual hallucinations occurred on dosing days and resolved within a day, and serious suicidal events were rare and mainly in lower‑dose or control arms. The company plans to meet the FDA to discuss rolling NDA submission and expects to complete an NDA for COMP360 in Q4, supported by Breakthrough Therapy designation.
Compass Pathways reported strongly positive topline results from both pivotal Phase 3 trials of its COMP360 psilocybin treatment for treatment‑resistant depression. In COMP005, a single 25 mg dose showed a highly statistically significant mean MADRS improvement versus placebo of -3.6 points at Week 6 (p<0.001), with rapid onset from the day after dosing and durability out to Week 26 for many responders. In COMP006, two 25 mg doses given three weeks apart achieved a -3.8‑point difference versus 1 mg at Week 6 (p<0.001), with 39% of patients reaching a clinically meaningful ≥25% MADRS reduction. Across more than 800 treated patients in these Phase 3 arms, COMP360 was generally well-tolerated; most adverse events such as headache, nausea, anxiety and visual hallucinations occurred on dosing days and resolved within a day, and serious suicidal events were rare and mainly in lower‑dose or control arms. The company plans to meet the FDA to discuss rolling NDA submission and expects to complete an NDA for COMP360 in Q4, supported by Breakthrough Therapy designation.
COMPASS Pathways plc reported an insider equity transaction by Chief Executive Officer and director Kabir Nath. On 02/02/2026, 16,181 Ordinary Shares were withheld by the company at $6.61 per share to cover tax obligations arising from vested restricted share units.
Following this non‑open‑market, tax‑withholding transaction, Nath directly beneficially owned 205,121 Ordinary Shares. The filing notes that the company’s Ordinary Shares may also trade as American Depositary Shares, with each ADS currently representing one Ordinary Share.
Compass Pathways entered a third amendment to its loan and security agreement with Hercules Capital, creating an amended term loan facility of up to $150 million across five tranches. The first tranche of $50 million is funded at closing, with a portion used to repay about $31.1 million of principal and PIK interest under the prior agreement. Additional tranches of up to $30 million each are tied to clinical and FDA approval milestones, plus a $20 million commercial milestone tranche and a further $20 million subject to Hercules’ investment committee.
The loans bear interest at the greater of 9.75% or 2.75% plus the Wall Street Journal prime rate, with interest-only payments until the first principal payment in the first quarter of 2029 and a scheduled maturity on January 5, 2031. The amendment includes facility and end-of-term charges, prepayment premiums, and is secured by substantially all personal property assets, along with minimum cash and performance covenants and customary default provisions.